[CAS NO. 932986-18-0]  Azoramide

Azoramide may have the protective effects of enhancing chaperone expression and reducing protein synthesis without inducing cytotoxicity and apoptosis. Azoramide may require the presence of intact IRE1 and PERK branches of the UPR to fully increase chaperone capacity. Azoramide is found to be a kind of compound with the dual property of not only boosting ER folding acutely but also activating ER chaperone capacity chronically to promote ER homeostasis. Its treatment potently protects cells against chemically-induced ER stress conditions. Azoramide preserves beta cell function and survival during metabolic ER stress. Azoramide pretreatment does not impair ER function as part of its initial action. Azoramide treatment leads to increased SERCA expression, resulting in enhanced retention of Ca+2 within the ER. Azoramide interacts with UPR pathways to promote resolution of ER stress and improve ER function.